Comment from Breakthrough Breast Cancer following the announcement that lapatinib (Tyverb) has been given a licence in the European Union as a treatment for women with HER2-positive advanced breast cancer, whose disease has stopped responding to Herceptin.Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer says: "Patients with advanced breast cancer usually have limited treatment options.
More...